CD177 and colorectal carcinoma: Recently, G protein‐coupled receptors (GPCRs) have become the focus of molecular‐targeted therapy.[4] As seven‐transmembrane receptors, GPCRs are a superfamily of cell surface receptors involved in human disease.[5] In response to extracellular stimuli, GPCRs are activated, changing their structural conformation to expose their binding sites to the downstream G protein subunit Gα and transduce signals intracellularly.[6] However, only 50 to 60 GPCRs have been implemented as drug targets, the majority of which remain in an orphan state, and research on GPCRs in CRC remains scarce.